Abstract
Background Information about the characteristics of stroke is crucial for improved screening, prevention, and treatment. The pattern of ischemic stroke in patients with nasopharyngeal carcinoma (NPC) is not well understood. The objective of this study is to investigate the etiology of ischemic stroke and the affected vascular territories in patients with NPC.
Methods The Taiwan National Health Insurance Research Database and the Taiwan Stroke Registry were combined to identify the following 2 cohorts: patients with NPC having a subsequent stroke (NPC cohort) and patients without NPC having a stroke (non-NPC cohort). Data pertaining to the period from 2006 to 2018 were analyzed. The TOAST (Trial of ORG 10 172 in Acute Stroke Treatment) subtype of ischemic stroke and the affected vascular territories were analyzed and compared between the 2 cohorts.
Results The NPC cohort comprised 277 patients, whereas the non-NPC cohort comprised 125 024 patients. The most common TOAST subtype of ischemic stroke was large-artery atherosclerosis (LAA) in the NPC cohort and small-vessel occlusion in the non-NPC cohort. The prevalence of LAA was considerably higher in the NPC cohort (41.9%) than in the non-NPC cohort (28.3%). The analysis of the affected vascular territories revealed that the incidence of brainstem stroke was significantly higher in the NPC cohort (25.4%) than in the non-NPC cohort (14.5%).
Conclusions Patients with NPC tend to have increased risks of LAA and brainstem ischemic stroke. Physicians should consider sparing the vertebral and basilar arteries during definitive radiotherapy for NPC. Long-term follow-up for patients with NPC may include brain magnetic resonance imaging. This study may guide radiation oncologists in clinical decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for conducting this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of China Medical University Hospital. Approval number: CMUH109-REC2-031(CR-3).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Research data will be shared upon request to the corresponding author.
